Thromboembolic events · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation probably leads to lower thromboembolic events compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review
Major bleeding · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation showed no clear difference in major haemorrhage compared with standard care (low certainty).
1 finding from 1 review
Minor haemorrhage · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation showed no clear difference in minor haemorrhage compared with standard care (moderate certainty).
1 finding from 1 review
Thromboembolic events · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
self‐management of oral anticoagulation probably leads to lower thromboembolic events compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · children with or without anaemia at baseline
Oral iron with antimalarial prophylaxis showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
RR 1.05 [0.52, 2.11]
728 participants
Low
Clinical malaria · children with or without anaemia at baseline
Oral iron with antimalarial prophylaxis leads to lower clinical malaria compared with placebo or no treatment (high certainty).
1 finding from 1 review
RR 0.54 [0.43, 0.67]
728 participants
High
Acquiring ability to walk · adults with SMA types II and III
1 finding from 1 review
Change in quality of life · adults with SMA types II and III
1 finding from 1 review
Change in pulmonary function · adults with SMA types II and III
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · adults with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · adults with SMA types II and III
1 finding from 1 review
Change in disability score · adults with SMA types II and III
1 finding from 1 review
Muscle strength · adults with SMA types II and III
1 finding from 1 review
Withdrawals due to adverse events · people with atopic dermatitis
1 finding from 1 review
Minor adverse events not leading to withdrawal of treatment · people with atopic dermatitis
1 finding from 1 review
Microbiology Emergence of resistant organisms · people with atopic dermatitis
1 finding from 1 review
Global change in composite ratings scale EASI ranges from 0 to 72 with higher values indicating greater severity. · people with atopic dermatitis
1 finding from 1 review
No of participants in whom S. aureus was isolated · people with atopic dermatitis
Oral antibiotic showed no clear difference in no of participants in whom S. aureus was isolated compared with placebo (low certainty).
1 finding from 1 review
Global outcome (good or excellent improvement in symptoms or signs, or both) · people with atopic dermatitis
Oral antibiotic showed no clear difference in global outcome (good or excellent improvement in symptoms or signs,… compared with placebo (low certainty).
1 finding from 1 review